Sirotnak F M, Schmid F A, Otter G M, Piper J R, Montgomery J A
Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Cancer Res. 1988 Oct 15;48(20):5686-91.
Studies are described examining a new class of 4-aminofolate analogues modified by an N to C conversion and alkyl substitution at the N-5 position of aminopterin and methotrexate. All of these analogues were equivalent to aminopterin and methotrexate as inhibitors of tumor cell dihydrofolate reductase (Ki = 3.49-5.16 pM). N to C conversion at the N-5 position of aminopterin reduced its influx (inferred from the change in Ki) 3-fold, but the same modification increased influx of methotrexate 2-3-fold in Sarcoma 180 cells. Alkylation (methyl or ethyl) of this position on 5-deazaaminopterin increased influx 3-fold, while a similar alteration of 5-deazamethotrexate increased influx 4-5-fold. Influx of the methotrexate analogues was increased a total of 14-fold as a result of these modifications. Similar differences among these analogues were observed for inhibition of Sarcoma 180 cell growth in culture. Inhibitory potency was in the ascending order methotrexate less than 5-deazamethotrexate less than 5-deazaaminopterin less than aminopterin less than 5-alkyl (methyl or ethyl) analogues of 5-deazaaminopterin and 5-deazamethotrexate (the ethyl analogues were 2-fold more inhibitory than the methyl analogues). All of the analogues examined were equivalent in regard to efflux from Sarcoma 180 cells. Differences in transport alone did not account for all of the increased inhibitory potency (up to 33-fold) of the 5-alkyl-5-deaza analogues compared to the parent compounds. The extent of polyglutamylation of 5-deazaaminopterin and 5-deazamethotrexate and their 5-alkyl derivatives in Sarcoma 180 cells was substantially less compared to aminopterin and equivalent to methotrexate. Transport inward of 5-deazaaminopterin in isolated crypt cell epithelium from mouse small intestine was 2-fold lower than aminopterin (influx Km = 14.2 +/- 2 microM), while influx of 5-deazamethotrexate was 2-fold greater than methotrexate (influx Km = 98.6 +/- 23). However, transport inward of all of the 5-alkyl derivatives of these 5-deaza analogues was intermediate [influx Km = 44.4 +/- 11 (SEM) to 49.8 +/- 12 microM] between values for aminopterin and methotrexate. These differences accounted, to some extent, for the reduced toxicity of the 5-alkyl-5-deazaaminopterin analogues compared to aminopterin and the increased toxicity of 5-methyl-5-deazamethotrexate compared to methotrexate. All of the 5-alkyl derivatives of aminopterin and methotrexate were more active in vivo than methotrexate against four murine tumor models.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究描述了对一类新型4-氨基蝶呤类似物的研究,这些类似物通过在氨基蝶呤和甲氨蝶呤的N-5位进行N到C的转化和烷基取代进行修饰。所有这些类似物作为肿瘤细胞二氢叶酸还原酶的抑制剂(Ki = 3.49 - 5.16 pM)与氨基蝶呤和甲氨蝶呤相当。氨基蝶呤N-5位的N到C转化使其内流(根据Ki的变化推断)降低了3倍,但相同的修饰使甲氨蝶呤在肉瘤180细胞中的内流增加了2 - 3倍。5-脱氮氨基蝶呤该位置的烷基化(甲基或乙基)使内流增加了3倍,而5-脱氮甲氨蝶呤的类似改变使内流增加了4 - 5倍。由于这些修饰,甲氨蝶呤类似物的内流总共增加了14倍。在培养中对肉瘤180细胞生长的抑制方面,这些类似物也观察到了类似的差异。抑制效力的升序为甲氨蝶呤小于5-脱氮甲氨蝶呤小于5-脱氮氨基蝶呤小于氨基蝶呤小于5-脱氮氨基蝶呤和5-脱氮甲氨蝶呤的5-烷基(甲基或乙基)类似物(乙基类似物的抑制作用比甲基类似物强2倍)。所检测的所有类似物在从肉瘤180细胞外流方面相当。与母体化合物相比,5-烷基-5-脱氮类似物增加的抑制效力(高达33倍)不能仅由转运差异来解释。与氨基蝶呤相比,肉瘤180细胞中5-脱氮氨基蝶呤和5-脱氮甲氨蝶呤及其5-烷基衍生物的多聚谷氨酸化程度显著降低,且与甲氨蝶呤相当。从小鼠小肠分离的隐窝细胞上皮中,5-脱氮氨基蝶呤的向内转运比氨基蝶呤低2倍(内流Km = 14.2 +/- 2 microM),而5-脱氮甲氨蝶呤的内流比甲氨蝶呤大2倍(内流Km = 98.6 +/- 23)。然而,这些5-脱氮类似物的所有5-烷基衍生物的向内转运介于氨基蝶呤和甲氨蝶呤的值之间[内流Km = 44.4 +/- 11(SEM)至49.8 +/- 12 microM]。这些差异在一定程度上解释了5-烷基-5-脱氮氨基蝶呤类似物与氨基蝶呤相比毒性降低以及5-甲基-5-脱氮甲氨蝶呤与甲氨蝶呤相比毒性增加的原因。氨基蝶呤和甲氨蝶呤的所有5-烷基衍生物在体内对四种小鼠肿瘤模型的活性均高于甲氨蝶呤。(摘要截断于400字)